Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole sodium
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Esomeprazole sodium is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD) and other acid-related conditions. It works by irreversibly binding to the H+/K+-ATPase enzyme at the secretory surface of gastric parietal cells, inhibiting the final step in gastric acid production. This results in reduced gastric acid secretion that persists longer than 24 hours. It is available as an injectable formulation for intravenous administration.
- Brand names
- Nexium IV
- Other names
- Esomeprazole ODTEsomeprazole delayed-release orally disintegrating tablets
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on esomeprazole sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole sodium.